Under Armour (NYSE:UAA)- Stocks Highjack By Analysts Estimates: Sealed Air Corporation (NYSE:SEE)

Under Armour, Inc. (NYSE:UAA) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.65% to close at $29.23 with the total traded volume of 2.73 Million shares.

Fundamentalist can give brighter side of a picture but an analyst can glow the darker parts stored in any investment. Let us view how analysts have ranked UAA in recent few months. In ratings table the UAA given BUY ratings by 16 analysts in current phase and 1 analyst suggest it as overweight security. The 1 number of analyst/s have SELL recommendation for current month on UAA. While 19 number of analysts gave ratings for HOLD in current. As per remarks given by WSJ, overall consensus pool recommend it as Overweight security.

The stock was assessed in terms of profitability as current quarter EPS estimate trends showed $0.25 at current month while compared with $0.25 in a month ago. The stock next year first quarter current estimate trend for EPS was for $0.03 and on annual basis FY 2016 estimate trends at current was for $0.60 as compared to one month ago of $0.60, and for next year per share earnings estimates have $0.69.

The firm has institutional ownership of 85%, while insider ownership included 0.10%. Its price to sales ratio ended at 2.56. UAA attains analyst recommendation of 2.30 with week’s performance of -2.73%.

Sealed Air Corporation (NYSE:SEE) [Trend Analysis] plunged reacts as active mover, shares a decrease -0.44% to traded at $45.51 and the percentage gap between open changing to regular change was -0.13%. The SEE held a rough session during the week but was ready to get some critical analysis. The stock was assessed by a pool of analysts at WSJ and came out with some serious outcomes not to be avoided before making investment. The SEE ratings chart showed that 7 gave HOLD ratings for the current month as 2 analysts opting for Overweight option for same period. For stocks’ current month, 9 analysts opted for BUY ratings. The stock price target chart showed average price target of 53 as compared to current price of 45.51.

Taking look on per share earnings estimates, its next year first quarter current estimate trend for EPS was for $0.56 and on annual basis FY 2016 estimate trends at current was for $2.60 as compared to one month ago of $2.60, and for next year per share earnings estimates have $2.98.

The firm’s current ratio calculated as 1 for the most recent quarter. The firm past twelve months price to sales ratio was 1.29 and price to cash ratio remained 26.38. As far as the returns are concern, the return on equity was recorded as 72.60% and return on investment was 11.30% while its return on asset stayed at 5.40%. The firm has total debt to equity ratio measured as 8.43.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *